| (Values in U.S. Thousands) | Jun, 2020 | Jun, 2019 | Jun, 2018 | Jun, 2017 | Jun, 2016 |
| Sales | 8,750 | 9,350 | 39,410 | 13,570 | 13,860 |
| Sales Growth | -6.42% | -76.28% | +190.42% | -2.09% | -72.06% |
| Net Income | -9,360 | -14,350 | 4,970 | -13,830 | -11,990 |
| Net Income Growth | +34.77% | -388.73% | +135.94% | -15.35% | -177.56% |
Pharmaxis Ltd ADR (PXSLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Pharmaxis develops innovative pharmaceutical products to treat human respiratory and autoimmune diseases. Its development pipeline of products include AridolTM for asthma, BronchitolTM for cystic fibrosis and chronic obstructive pulmonary disease and PXS64 for multiple sclerosis.
Fiscal Year End Date: 06/30